These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 8091744)

  • 1. Hepatitis A viral safety of plasma-derived factor VIII concentrate Koate-HP.
    Mitra G; Dobkin M; Dumas M; Ng P; Roldan G; Galloway C
    Vox Sang; 1994; 67 Suppl 1():80-2. PubMed ID: 8091744
    [No Abstract]   [Full Text] [Related]  

  • 2. Distribution of hepatitis A antibody over a process for the preparation of a high-purity factor VIII concentrate.
    Hart H; Jones A; Cubie H; McIntosh RV; Cuthbertson B
    Vox Sang; 1994; 67 Suppl 1():51-5. PubMed ID: 8091738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of hepatitis A virus in a factor VIII preparation by antigen capture/PCR.
    Normann A; Graff J; Flehmig B
    Vox Sang; 1994; 67 Suppl 1():57-60; discussion 61. PubMed ID: 8091739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of intermediate and high purity factor VIII products in the treatment of von Willebrand disease.
    Hanna WT; Bona RD; Zimmerman CE; Carta CA; Hebert GZ; Rickles FR
    Thromb Haemost; 1994 Feb; 71(2):173-9. PubMed ID: 8191394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pasteurized, monoclonal antibody factor VIII concentrate: establishing a new standard for purity and viral safety of plasma-derived concentrates.
    Goldsmith JC
    Blood Coagul Fibrinolysis; 2000 Mar; 11(2):203-15. PubMed ID: 10759015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Viral safety of a new highly purified factor VIII (OCTATE).
    Biesert L; Lemon S; Goudeau A; Suhartono H; Wang L; Brede HD
    J Med Virol; 1996 Apr; 48(4):360-6. PubMed ID: 8699169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Removal and inactivation of hepatitis A virus (HAV) during processing of factor VIII concentrates.
    Hamman J; Zou J; Horowitz B
    Vox Sang; 1994; 67 Suppl 1():72-6; discussion 77. PubMed ID: 8091742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dry-heat treatment process for enhancing viral safety of an antihemophilic factor VIII concentrate prepared from human plasma.
    Kim IS; Choi YW; Kang Y; Sung HM; Shin JS
    J Microbiol Biotechnol; 2008 May; 18(5):997-1003. PubMed ID: 18633304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Viral safety of plasma-derived factor VIII and IX concentrates.
    Ludlam CA
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S19-23. PubMed ID: 9351532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. "In vitro" and in animal model studies on a double virus-inactivated factor VIII concentrate.
    Arrighi S; Rossi R; Borri MG; Lesnikov V; Lesnikova M; Franco E; Divizia M; De Santis ME; Bucci E
    Thromb Haemost; 1995 Sep; 74(3):868-73. PubMed ID: 8571312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis A virus sequence detected in clotting factor concentrates associated with disease transmission.
    Robertson BH; Alter MJ; Bell BP; Evatt B; McCaustland KA; Shapiro CN; Sinha SD; Souci JM
    Biologicals; 1998 Jun; 26(2):95-9. PubMed ID: 9811512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Affinity chromatography to remove viruses during preparation of plasma derivatives.
    Lawrence JE
    Dev Biol Stand; 1993; 81():191-7. PubMed ID: 8174803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Removal/neutralization of hepatitis A virus during manufacture of high purity, solvent/detergent factor VIII concentrate.
    Lemon SM; Murphy PC; Smith A; Zou J; Hammon J; Robinson S; Horowitz B
    J Med Virol; 1994 May; 43(1):44-9. PubMed ID: 8083647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human parvovirus PARV4 in clotting factor VIII concentrates.
    Fryer JF; Hubbard AR; Baylis SA
    Vox Sang; 2007 Nov; 93(4):341-7. PubMed ID: 18070279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of hepatitis A virus RNA in commercially available factor VIII preparation.
    Normann A; Graff J; Gerritzen A; Brackmann HH; Flehmig B
    Lancet; 1992 Nov; 340(8829):1232-3. PubMed ID: 1359306
    [No Abstract]   [Full Text] [Related]  

  • 16. Porcine factor VIII: past, present and future.
    Hay CR
    Haematologica; 2000 Oct; 85(10 Suppl):21-4; discussion 24-5. PubMed ID: 11187865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful clinical use of a plasma-derived, dual virus inactivated factor VII concentrate incorporating solvent-detergent and dry heat treatment.
    Smith MP; Rice KM; Savidge GF
    Thromb Haemost; 1997 Feb; 77(2):406-7. PubMed ID: 9157608
    [No Abstract]   [Full Text] [Related]  

  • 18. Hepatitis A virus infection in tamarins: experimental transmission via contaminated factor VIII concentrates.
    Chudy M; Stahl-Hennig C; Berger A; Nübling CM; Hunsmann G; Rabenau HF; Löwer J
    J Infect Dis; 2002 Apr; 185(8):1170-3. PubMed ID: 11930328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A retrospective survey on the safety of Replenate, a high-purity factor VIII concentrate.
    Gascoigne EW; Dash CH; Harman C; Wilmot D
    Pharmacoepidemiol Drug Saf; 2004 Apr; 13(4):243-52. PubMed ID: 15255091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis A virus PCR analysis of clotting factor concentrates and elimination of non-enveloped viruses in their manufacture.
    Mohr H; Lambrecht B; Marks F; Tschech A
    Vox Sang; 1994; 67 Suppl 1():78-9. PubMed ID: 8091743
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.